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 3 
ABSTRACT (247 words) 68 
 69 
Aims: We aimed to evaluate the impact of age on the performance of the European Society of 70 
Cardiology (ESC) 0/1h-algorithms and to derive and externally validate alternative cut-offs 71 
specific to older patients.  72 
Methods and Results: We prospectively enrolled patients presenting to the emergency 73 
department with symptoms suggestive of acute myocardial infarction (AMI) in three large 74 
diagnostic studies. Final diagnoses were adjudicated by two independent cardiologists. High-75 
sensitivity cardiac troponin (hs-cTn) T and I concentrations were measured at presentation and 76 
after 1h. Patients were stratified according to age (<55 years [young], ≥55 to <70 years [middle-77 
age], ≥70 years [old]). Rule-out safety of the ESC hs-cTnT-0/1h-algorithm was very high in all 78 
age-strata: sensitivity 100% [95%CI, 94.9-100]) in young, 99.3% [95%CI, 96.0-99.9]) in 79 
middle-age, and 99.3% [95%CI, 97.5-99.8]) in old patients. Accuracy of rule-in decreased with 80 
age: specificity 97.0% [95%CI, 95.8-97.9]) in young, 96.1% [95%CI, 94.5-97.2]) in middle-81 
age, and 92.7% [95%CI, 90.7-94.3]) in older patients. Triage efficacy decreased with increasing 82 
age (young 93%, middle-age 80%, old 55%, p<0.001). Similar results were found for the ESC 83 
hs-cTnI-0/1h-algorithm. Alternative, slightly higher cut-off concentrations optimized for older 84 
patients maintained very high safety of rule-out, increased specificity of rule-in (p<0.01), 85 
reduced overall efficacy for hs-cTnT (p<0.01), while maintaining efficacy for hs-cTnI. Findings 86 
were confirmed in two validation cohorts (n=2767). 87 
Conclusion: While safety of the ESC 0/1h-algorithms remained very high, increasing age 88 
significantly reduced overall efficacy and the accuracy of rule-in. Alternative slightly higher 89 
cut-off concentrations may be considered for older patients, particularly if using hs-cTnI. 90 
 91 
Keywords: Age, high-sensitivitiy cardiac troponin, guidelines, 0/1h-algorithm, diagnosis of 92 
AMI. 93 
 4 
Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT00470587, number 94 
NCT00470587 and NCT02355457 (BACC) 95 
  96 
Abbreviations 97 
APACE – Advantageous Predictors of Acute Coronary Syndromes Evaluation 98 
 99 
BACC – Biomarkers in Acute Cardiac Care 100 
 101 
TRAPID-AMI – High-sensitivity cardiac Troponin T assay for RAPID rule-out of AMI 102 
 103 
ED – Emergency department 104 
AMI – Acute myocardial infarction 105 
NSTEMI – Non-ST-segment elevation myocardial infarction 106 
ECG – Electrocardiography 107 
 108 
cTn – Cardiac troponin 109 
hs-cTn – High-sensitivity cardiac troponin 110 
eGFR – Estimated glomerular filtration rate 111 
NPV – Negative predictive value 112 
PPV – Positive predictive value 113 
IQR – Interquartile range 114 
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Introduction 123 
In patients presenting with symptoms suggestive of acute myocardial infarction (AMI), rapid 124 
identification of AMI as a life-threatening disorder, but also rapid and accurate rule-out of AMI 125 
has enormous medical and economic value.1–3 Recently, diagnostic strategies applying high-126 
sensitivity cardiac troponin (hs-cTn) T or I assays, including the European Society of 127 
Cardiology (ESC) 0/1h-algorithms, have been developed and facilitate the early triage towards 128 
rule-out or rule-in of AMI.1–11 129 
Beyond the presence or absence of AMI, age seems to be the most important confounder 130 
of hs-cTnT and hs-cTnI blood concentrations.12–21 Mildly elevated hs-cTnT and hs-cTnI blood 131 
concentrations are common in elderly individuals without apparent ischemic symptoms.2,3,12–21 132 
Unfortunately, the impact of age on the diagnostic performance of the ESC 0/1h-algorithms is 133 
incompletely understood. 134 
To address this major gap in knowledge, we prospectively investigated the impact of 135 
age on the performance of the ESC 0/1h-algorithms in a large multicentre diagnostic study 136 
using central adjudication. In a second step, the age-specific findings and aged-optimized 137 
alternative cut-off concentrations for older patients derived in this multicentre study were 138 
externally validated in two additional diagnostic studies.  139 
 140 
 141 
 142 
 143 
 144 
 145 
 146 
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Methods 148 
Study design and oversight 149 
We enrolled adult patients presenting with suspected AMI to the ED in three large prospective 150 
diagnostic studies carried out according to the principles of the Declaration of Helsinki and 151 
approved by the local ethics committees: Advantageous Predictors of Acute Coronary 152 
Syndrome Evaluation (APACE, main cohort),5,7–10,17,22–26 Biomarkers in Acute Cardiac Care 153 
(BACC, first validation cohort)27 and High-sensitivity cardiac Troponin T assay for RAPID 154 
rule-out of AMI (TRAPID-AMI, second validation cohort).28 Written informed consent was 155 
obtained from all patients.  156 
The authors designed the study, gathered, and analysed the data according to the 157 
STARD guidelines29 for studies of diagnostic accuracy (Supplemental Table 1), vouched for 158 
the data and analysis, wrote the paper, and decided to publish. Routine clinical assessment and 159 
detailed methodological descriptions of all three cohorts are given in the Online Supplemental. 160 
 161 
The ESC hs-cTnT and hs-cTnI 0/1h-algorithms 162 
The concept of the ESC 0/1h-algorithms is described in detail in the Online Supplemental and 163 
shown in Supplemental Figure 1.  164 
 165 
Stratification of patients according to age 166 
We aimed to stratify patients by age into three equally large cohorts. Based on previous findings 167 
from APACE5,8–10,22,25,31–34 we assumed that the following three age-strata should yield near-168 
equal group-size: <55 years (young), ≥55 to <70 years (middle-age), ≥70 years (old). 169 
 170 
Statistical analysis 171 
Safety for rule-out was quantified by the resulting sensitivity (and negative predictive value 172 
[NPV]), accuracy for rule-in was quantified by the resulting specificity (and positive predictive 173 
value [PPV]) for NSTEMI and overall efficacy was quantified by the percentage of patients 174 
triaged either towards rule-out or rule-in by the respective strategy. Time since chest pain onset 175 
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(cpo) was determined at the time of first study blood draw. In the main cohort, subgroup 176 
analyses were performed in early presenters (cpo ≤2h), late presenters (cpo >6h) and in very 177 
old patients (age ≥80 years). 178 
All hypothesis testing was two-tailed, and P values of less than 0.05 were considered to 179 
indicate statistical significance without adjustments for multiple testing. Statistical analyses 180 
were performed using SPSS for Windows, version 24.0 (SPSS Inc, Chicago, IL), MedCalc, 181 
version 9.6.4.0 (MedCalc Software, Ostend, Belgium), and R (Version 3.3.1, Vienna, Austria). 182 
Detailed information is given in the Online Supplemental Methods. 183 
 184 
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Results 199 
Main cohort 200 
Study cohort and characteristics of patients  201 
From April 2006 to August 2015, 3123 patients were available for the analysis of the ESC hs-202 
cTnT 0/1h-algorithm and 2828 patients for the analysis of the ESC hs-cTnI 0/1h-algorithm 203 
(Supplemental Figure 2). Older patients differed in multiple characteristics from younger and 204 
middle-aged patients, particularly a higher prevalence of pre-existing cardiovascular disorders 205 
including AMI and stroke (Table 1, Supplemental Table 2).  206 
 207 
Adjudicated final diagnosis 208 
Among patients with complete dataset of hs-cTnT, the adjudicated final diagnosis was NSTEMI 209 
in 491/3123 patients (16%), unstable angina in 301/3123 (10%), cardiac symptoms of origin 210 
other than coronary artery disease such as tachyarrhythmia, Tako-Tsubo cardiomyopathy, heart 211 
failure or myocarditis in 476/3123 (15%), non-cardiac symptoms in 1728/3123 (55%) and 212 
unknown in 127/3123 patients (4%). The prevalence of NSTEMI increased with increasing age 213 
(young 6.4%, middle-aged 15%, old 27%, p<0.001). Distribution of final diagnoses was similar 214 
in patients with complete dataset of hs-cTnI (Online Supplemental Results).  215 
 216 
Hs-cTn concentrations at presentation according to age and final diagnoses and 217 
interaction between age and hs-cTn 218 
Concentrations of hs-cTnT and hs-cTnI at presentation showed a moderate-to-high correlation 219 
with age in both datasets (ρ=0.6 for hs-cTnT and ρ=0.49 for hs-cTnI, respectively, both 220 
p<0.001). Old patients had significantly higher hs-cTnT and hs-cTnI concentrations at 221 
presentation than young and middle-aged patients, particularly in patients with final diagnoses 222 
other than NSTEMI (Supplemental Figure 3A+B). The Interaction between age and hs-cTnT 223 
concentrations for NSTEMI was significant (p<0.001), but not for hs-cTnI (p=0.31). Online 224 
Supplemental Results, Online Supplemental Figure 4A+B). 225 
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Diagnostic accuracy of hs-cTnT and hs-cTnI 226 
AUCs of hs-cTnT concentrations at presentation in young, middle-aged, and old patients were 227 
0.96 (95%CI, 0.94-0.98), 0.93 (95%CI, 0.91-0.95), and 0.89 (95%CI, 0.87-0.91), respectively. 228 
AUCs of hs-cTnI concentrations at presentation in young, middle-aged, and old patients were 229 
0.95 (95%CI, 0.93-0.97), 0.92 (95%CI, 0.90-0.94), and 0.87 (95%CI, 0.85-0.90), respectively 230 
(Figure 1A). 231 
 232 
Diagnostic performance of the ESC hs-cTnT 0/1h-algorithm according to age  233 
Among 1122 (36%) young patients, 956/1122 (85% [95%CI, 83-87]) were triaged towards rule-234 
out (sensitivity 100% [95%CI, 94.9-100], NPV 100% [95%CI, 99.6-100]), 92/1122 (8% 235 
[95%CI, 7-10]) patients were triaged towards rule-in (specificity 97.0% [95%CI, 95.8-97.9], 236 
PPV 66.3% [95%CI, 56.2-75.1]).  237 
 Among 935 (30%) middle-aged patients, 606/935 (65% [95%CI, 62-68]) were triaged 238 
towards rule-out (sensitivity 99.3% [95%CI, 96.0-99.9], NPV 99.8% [95%CI, 99.1-100]), 239 
141/935 (15% [95%CI, 13-17]) patients triaged towards rule-in (specificity 96.1% [95%CI, 240 
94.5-97.2], PPV 78.0% [95%CI, 70.5-84.1]).  241 
  Among 1066 (34%) old patients, 317/1066 (30% [95%CI, 27-33]) were triaged towards 242 
rule-out (sensitivity 99.3% [95%CI, 97.5-99.8], NPV 99.4% [95%CI, 97.7-99.8]), 272/1066 243 
(25% [95%CI, 23-28]) patients were triaged towards rule-in (specificity 92.7% [95%CI, 90.7-244 
94.3], PPV 79.0% [95%CI, 73.8-83.5]; Table 2A, Figure 2A).  245 
One middle-aged and 2 old patients with NSTEMI were missed (Supplemental Table 246 
3). Detailed diagnostic performance of the ESC hs-cTnT 0/1h-algorithm in decades of age is 247 
shown in Figure 2B.  248 
 249 
Diagnostic performance of the ESC hs-cTnI 0/1h-algorithm according to age  250 
Overall, similar findings emerged when assessing the diagnostic performance of the ESC hs-251 
cTnI 0/1h-algorithm according to age (Figure 3, Table 3A, Supplemental Table 3).  252 
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Derivation of alternative cut-off criteria for the ESC hs-cTnT 0/1h-algorithm 253 
Optimal alternative cut-offs for rule-out were <8ng/L at presentation in patients presenting with 254 
a cpo >3h or <12ng/L at presentation and an absolute 1h-change <3ng/L. The safety was 255 
identical to the original ESC hs-cTnT 0/1h-algorithm, but the proportion of patients eligible for 256 
direct rule-out increased from 2.2% (95%CI, 1.3-3.1) to 11% (95%CI, 8.9-13). The proportion 257 
of patients ruled-out overall was identical to that of the original ESC 0/1h-algorithm. For rule-258 
in, optimal alternative cut-offs were ≥80ng/L at presentation or an absolute 1h-change ≥6ng/L. 259 
These cut-offs improved specificity from 92.7% (95%CI, 90.7-94.3) to 96.8% (95%CI, 95.3-260 
97.8, p<0.01) and PPV from 79.0% (95%CI, 73.8-83.5) to 87.8% (95%CI, 82.6-91.6, p=0.04). 261 
However, the proportion of patients ruled-in for NSTEMI decreased from 25% (95%CI, 23-28) 262 
to 21% (95%CI, 18-24) and from 18% [95%CI, 16-21] to 12% [95%CI, 10-14] for direct rule-263 
in; Supplemental Table 4A). Accordingly, overall efficacy decreased from 55% to 51% 264 
(p<0.001). 265 
 266 
Derivation of alternative cut-off criteria for the ESC hs-cTnI 0/1h-algorithm 267 
Optimal alternative cut-offs for rule-out were <4ng/L at presentation in patients presenting with 268 
cpo >3h or <6ng/L at presentation and an absolute 1h-change <3ng/L. The safety was similar 269 
to the original ESC hs-cTnI 0/1h-algorithm (NPV 97.5% vs. 98.1%, p=0.67), and the proportion 270 
of patients eligible for rule-out increased from 25% (95%CI, 22-27) to 32% (95%CI, 29-35) 271 
and for direct rule-out from 1.4% (95%CI, 0.7-2.4) to 12% (95%CI, 10-14) (Supplemental 272 
Table 4B). For rule-in, optimal alternative cut-offs were ≥100ng/L at presentation or an 273 
absolute 1h-change ≥8ng/L. These cut-offs significantly improved specificity from 86.4% 274 
(95%CI, 83.7-88.7) to 90.6% (95%CI, 88.3-92.5, p=0.01), while the increase in PPV did not 275 
reach statistical significance 67.9% (95%CI, 62.4-72.9) to 74.2% (95%CI, 68.6-79.2, p=0.11). 276 
Again, the proportion of patients ruled-in for NSTEMI decreased from 31% (95%CI, 28-34) to 277 
27% (95%CI, 24-30) and from 23% [95%CI, 20-25] to 16% [95%CI, 14-19] for direct rule-in; 278 
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Table 3A Supplemental Table 4B). Accordingly, overall efficacy increased from 56% to58% 279 
(p<0.03). 280 
 281 
Sex-specific cut-off criteria for the ESC 0/1h-algorithms for use in older patients  282 
The diagnostic performance of derived and validated sex-specific cut-off combinations for use 283 
in older patients is shown in the Online Supplemental Results and Online Supplemental 284 
Table 5A-C.  285 
 286 
Subgroup analyses in very early presenters, late presenters and very old patients  287 
Among 3123 patients with hs-cTnT, 830/3123 patients (27%) presented within 2h from cpo. 288 
E.g. in old patients (n=226), 64/226 (28%) were ruled-out (sensitivity 98.5%), 62/226 (27%) 289 
ruled-in (specificity 91.1%), and the remaining 100/226 (44%) patients classified as observe 290 
(Supplemental Figure 5A). Similar results were obtained for hs-cTnI (Supplemental Figure 291 
5B). The performance of both ESC hs-cTn 0/1h-algorithms in late presenters and very old 292 
patients (age ≥80 years) is given in the Online Supplemental.  293 
 294 
Prognostic performance of the ESC hs-cTnT/I 0/1h-algorithms to predict death during 295 
follow-up  296 
Survival of young patients triaged towards rule-out, observe and rule-in was 100% at 30-days 297 
for all age groups and 99.6%, 96.6%, and 95.1% at 2-years, respectively (all p<0.001). Among 298 
middle-aged patients, survival was 99.8%, 98.4%, and 100% at 30-days, and 99.1%, 93.1%, 299 
and 96.8% at 2-years, respectively (all p<0.001, p=0.06 for comparison between observe and 300 
rule-in). Among old patients, survival was 99.7%, 98.7%, and 94.5% at 30-days, and 93.6%, 301 
82.2% and 75.4% at 2-years, respectively (all p<0.001; Supplemental Figure 6A).  302 
 Similar findings emerged when assessing the prognostic performance of the ESC hs-303 
cTnI 0/1h-algorithm (Supplemental Figure 6B) and for the prediction of MACE within 30 304 
days (Online Supplemental Results). 305 
 306 
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Validation Cohorts 307 
Overall, the characteristics of patients in validation cohort 1 and validation cohort 2 were 308 
similar to those of the main cohort (Supplemental Table 6+7).  309 
 310 
Diagnostic accuracy of hs-cTnT  311 
AUCs of hs-cTnT and hs-cTnI concentrations at presentation in young, middle-aged, and old 312 
patients in both validation cohorts were similar to AUCs in the main cohort (Figure 1B+C).  313 
 314 
Diagnostic performance of the official ESC hs-cTn 0/1h-algorithms and validation of the 315 
alternative cut-off criteria in old patients  316 
In both validation cohorts, findings for the ESC hs-cTnT 0/1h-algorithm (and for the hs-cTnI 317 
0/1h-algorithm in the first validation cohort) were similar to the findings of the main cohort. 318 
While safety remained high in older patients, specificity among patients triaged towards rule-319 
in and particularly overall efficacy decreased with increasing age (Figure 4, Table 2B+C, 320 
Table 3B, Supplemental Figure 7-9).  321 
 322 
Prognostic performance of the ESC hs-cTn 0/1h-algorithms to predict death during 323 
follow-up  324 
Prognostic performance of the ESC 0/1h-algorithms in both validation cohorts was similar to 325 
the prognostic performance in the main cohort (Online Supplemental Results, Supplemental 326 
Figure 10). 327 
 328 
 329 
 330 
 331 
 332 
 333 
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Discussion  334 
This large multicentre study quantified the impact of age on the performance of the ESC 0/1h-335 
algorithms. In a second step, we derived and externally validated alternative cut-off criteria 336 
optimized for the use in older patients. We report eight major findings: 337 
First, increasing age was associated with a higher prevalence of pre-existing 338 
cardiovascular disorders. Second, while patients adjudicated to have NSTEMI had comparable 339 
hs-cTnT and hs-cTnI concentrations among the three age-strata, hs-cTnT and hs-cTnI 340 
concentrations were significantly higher in older patients with other causes of acute chest 341 
discomfort. This finding seems at least in part explained by the higher prevalence of pre-342 
existing cardiovascular disorders and their association with chronic myocardial injury in older 343 
patients. Third, accordingly the overlap in hs-cTnT and hs-cTnI concentrations between 344 
NSTEMI and other causes of acute chest discomfort was larger resulting in a lower AUC with 345 
increasing age. The interaction term (hs-cTn*age) for NSTEMI was statistically significant 346 
when using hs-cTnT, but not when using hs-cTnI, possibly suggesting different effects of aging 347 
on hs-cTnT versus hs-cTnI concentrations. Fourth, the prevalence of NSTEMI increased 348 
substantially with increasing age and was more than four-times higher in older versus younger 349 
patients. Fifth, age had a major impact on the overall diagnostic performance of the ESC 0/1h-350 
algorithm: while safety as quantified by sensitivity and NPV was very high in all age-strata, the 351 
percentage of patients assigned towards rule-out, the specificity among patients triaged towards 352 
rule-in and particularly overall efficacy decreased with increasing age. As a consequence, the 353 
percentage of old patients remaining in the observe zone and usually requiring additional 354 
diagnostic testing including a 3h-sample of hs-cTn and cardiac imaging was nearly twice as 355 
high as in middle-aged and more than four-times as high as in young patients. Due to the 356 
increase in AMI prevalence with age, PPV remained high in older patients. Sixth, use of 357 
individualized slightly higher cut-offs in older patients maintained very high safety of rule-out, 358 
increased specificity of rule-in, reduced overall efficacy for hs-cTnT, while maintaining 359 
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efficacy for hs-cTnI. Accordingly, the use of slightly higher cut-off concentrations may be 360 
considered, particularly if using hs-cTnI. Still, the overall improvement achieved was modest 361 
and needs to be balanced against the increased complexity created by specific cut-offs in elderly 362 
patients. Using sex-specific cut-off criteria versus modified cut-off criteria in older patients did 363 
not further increase the overall diagnostic performance of both ESC 0/1h-algorithms. Beyond 364 
age, also the time from chest pain onset, sex, and renal function have been shown to affect hs-365 
cTnT and hs-cTnI concentrations. Although preliminary evidence suggests that the effect of 366 
these additional confounders overall is smaller as compared to that of age,1,2,12,15,35 367 
computerized integration of all confounders might be the most accurate approach once 368 
convenient physician-information technology interfaces become available. Seventh, while the 369 
vast majority of findings for the ESC 0/1h-algorithm using hs-cTnI mirrored the findings for 370 
the ESC 0/1h-algorithm using hs-cTnT, safety of rule-out and accuracy of rule-in were slightly 371 
lower for hs-cTnI as compared to hs-cTnT. At first glance, this finding is surprising as both 372 
assays seem to have comparable diagnostic accuracy for NSTEMI,23 and hs-cTnI-Architect 373 
seems to have even higher analytical sensitivity as compared to hs-cTnT-Elecsys.36 This finding 374 
is therefore more likely related to the inherent verification bias in favor of hs-cTnT (available 375 
among many other information for the adjudication) as compared to hs-cTnI (not available for 376 
the adjudication) and the rare, but previously described analytical discrepancies between hs-377 
cTnI and hs-cTnT.8,32 Eighth, irrespective of age, patients triaged towards rule-out had very 378 
high 30-day survival rates of 99-100%. As expected, 30-day and 1-year or 2-year survival rates 379 
were lower in older patients as compared to younger patients. 380 
Our findings extend and corroborate data previously obtained for the diagnostic 381 
performance of the ESC 0/1h-algorithm assessed in all-comers with acute chest 382 
discomfort.7,8,10,22,34 These findings also extend and corroborate more general observations 383 
made for the use of hs-cTn in elderly patients.37  384 
The clinical utility of the ESC 0/1h-algorithms also remained high in very old patients 385 
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(≥80 years) and those presenting very early after chest pain onset. While patients presenting 386 
early to the ED were more frequently ruled-in by significant 1h-delta changes, late presenters 387 
were primarily ruled-in due to markedly elevated cardiac troponin concentrations. This can be 388 
explained by the fact that the increase in cardiac troponin concentrations is time-dependent. 389 
Due to the higher prevalence of NSTEMI, PPV in older patients was even higher (70-80%) as 390 
in younger patients, and in a range that most experts consider an acceptable likelihood to initiate 391 
invasive management in the majority of these patients. The additional use of short-term changes 392 
as criteria within the ESC 0/1h-algorithms at least in part was able to compensate for the 393 
substantially lower specificity of mild elevations in hs-cTn in older patients.37  394 
The lower efficacy observed in older patients is not unique to the ESC 0/1h-algorithms, 395 
but seems to be a universal phenomenon of all currently available diagnostic algorithms.2,3,38 396 
The higher prevalence of cardiovascular comorbidities in older patients invariably reduces the 397 
diagnostic performance of clinical assessment, the ECG, hs-cTn, and cardiac imaging.2,3,38  398 
The exact pathophysiological mechanisms resulting in cardiomyocyte injury in the 399 
aging heart are incompletely understood, but seem to include the effect of pre-existing 400 
cardiovascular disorders such as previous AMI, hypertensive heart disease, as well as 401 
myocardial fibrosis.2,3,39 402 
It is important to highlight that irrespective of the use of the uniform or individualized 403 
cut-offs in older patients, the ESC 0/1h-algorithms should always be used in conjunction with 404 
full clinical assessment and the ECG. Accordingly, the final sensitivity achieved by the 405 
combination of both ESC 0/1h-algorithms with clinical assessment and the ECG will be even 406 
slightly higher as that reported for the ESC 0/1h-algorithms only. Vice-versa, efficacy will be 407 
slightly lower as the clinician will overrule the triage recommendation provided by the 408 
algorithm in some patients. 409 
Some limitations merit consideration when interpreting these findings. First, our study 410 
was conducted in ED patients with symptoms suggestive of AMI. Further studies are required 411 
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to quantify the utility of the ESC 0/1h-algorithms in patients with either a higher pre-test 412 
probability (e.g., in a coronary care unit setting) or in patients with a lower pre-test probability 413 
(e.g., in a general practitioner setting) for AMI. Second, no specific sample size calculation was 414 
performed. Although this secondary analysis from an ongoing multicenter study is one of the 415 
largest ever performed, it still may have been underpowered for some comparisons. Third, not 416 
all patients with acute chest pain had a second set of laboratory measurements at 1h. The most 417 
common reasons for missing blood samples were logistic issues in the ED that precluded blood 418 
draw around the 1h-window. However, it is unlikely that the absence of these patients 419 
significantly influenced our results. Fourth, although we used the most stringent methodology 420 
to adjudicate the presence or absence of AMI including central adjudication by experienced 421 
cardiologists and serial measurements of hs-cTn, we still may have misclassified a small 422 
number of patients.30 Fifth, our findings are specific to the two hs-cTn assays currently 423 
available for routine clinical care. Once other hs-cTn assays will become available for clinical 424 
care, additional studies will need to derive and validate a 0/1h-algorithm and examine whether 425 
our findings can be generalized to them. Finally, we cannot generalize our findings to patients 426 
with terminal kidney failure requiring dialysis, since they were excluded from this study.  427 
 428 
Conclusion  429 
While the safety of the ESC 0/1h-algorithms remained very high, increasing age significantly 430 
reduced overall efficacy and the accuracy of rule-in. Alternative slightly higher cut-off 431 
concentrations may be considered for older patients, particularly if using hs-cTnI. 432 
 433 
 434 
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Figure Legends 
 
Receiver operating characteristics curve and corresponding areas under the curves indicating 
diagnostic accuracy of hs-cTnT (blue) and hs-cTnI (orange) concentrations at presentation for 
the diagnosis of acute myocardial infarction in patients stratified according to age into young 
(<55 years), middle-age (≥55 to <70 years), and old (≥70 years) in (A) main cohort, (B) first 
validation cohort, and (C) second validation cohort. Hs-cTnT = high sensitivity cardiac troponin 
T; hs-cTnI = high-sensitivity cardiac troponin I. 
 
Diagnostic performance of the ESC hs-cTnT 0/1h-algorithm in patients stratified according to 
age into (A) young, middle-age, old, and (B) decades. (*) if chest pain onset >3h; Delta = 
unsigned change within the first hour; NSTEMI = non-ST-segment elevation myocardial 
infarction. Sens. = sensitivity; NPV = negative predictive value; Prev. = prevalence; Spec. = 
specificity; PPV = positive predictive value. hs-cTnT = high sensitivity cardiac troponin T. 
 
Diagnostic performance of the ESC hs-cTnI 0/1h-algorithm in patients stratified according to 
age into (A) young, middle-age, old, and (B) decades. (*) if chest pain onset >3h; Delta = 
unsigned change within the first hour; NSTEMI = non-ST-segment elevation myocardial 
Figure 1 
Diagnostic accuracy of hs-cTnT and hs-cTnI concentrations at 
presentation to the emergency department for the diagnosis of 
NSTEMI in patients stratified according to age  
Figure 2 Diagnostic performance of the ESC hs-cTnT 0/1h-algorithm according to age in the main cohort 
Figure 3 Diagnostic performance of the ESC hs-cTnI 0/1h-algorithm according to age in the main cohort 
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infarction. Sens. = sensitivity; NPV = negative predictive value; Prev. = prevalence; Spec. = 
specificity; PPV = positive predictive value. hs-cTnI = high sensitivity cardiac troponin I. 
 
Diagnostic performance of the (A) ESC hs-cTnT 0/1h-algorithm and (B) ESC hs-cTnI 0/1h-
algorithm using modified cut-off criteria for use in older patients (≥70 years). Red numbers 
indicate modified cut-off values that differ from the official cut-off criteria.  
 
Figure 4 Diagnostic performance of modified cut-off criteria for use in older patients (≥70 years) in all three study cohorts 
